EGFR and non-small cell lung carcinoma: Although the emergence of TKIs is a milestone for the treatment of advanced NSCLC, inevitable resistance will be observed after a few months of targeted therapy (EGFR-TKIs and ALK-TKIs) (Ohashi et al., 2013).